Kogenate FS is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with factor VIII deficiency due to hemophilia A. Kogenate FS can also be used for perioperative (before, during, and after surgery) care and for routine prophylaxis. Kogenate FS may reduce the risk of joint damage in children who have not developed joint damage. The technical name of Kogenate FS is Antihemophilic factor (recombinant).
Kogenate FS is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.
How do I take it?
Prescribing information states that Kogenate FS is given as an intravenous injection.
Kogenate FS comes as a powder that must be reconstituted before injection.
The FDA-approved label for Kogenate FS lists common side effects including rash, itching, hives, inflammation or redness at the injection site, central venous access device infections, and the development of inhibitors.
Rare but serious side effects listed for Kogenate FS include life-threatening hypersensitivity reactions.